Background: ELECT, a large phase 3 study of the long-acting somatostatin analog (SSA) LAN for symptomatic control of CS in NET patients showed significant improvement over PBO in % days with short-acting octreotide use as rescue medication. Here, we investigate reduction in use of rescue medication for LAN vs PBO in subgroups defined by baseline characteristics. Methods: Patients with histologically confirmed NETs and history of CS received double-blind LAN 120 mg (n=59) or PBO (n=56) every 4 wks for 16 wks, with access to short-acting octreotide for breakthrough symptoms (NCT00774930). Least-squares mean differences in % of days rescue octreotide use for LAN vs PBO were calculated by ANCOVA within subgroups. Results: The significant reduction for LAN vs PBO in rescue medication use in the overall population (Table; approximately one-third lower for LAN group relative to PBO group) was generally consistent with reductions favoring LAN over PBO across subgroups, except small subgroups in which CIs were wide (e.g. BMI ≥30). Conclusions: Beneficial effects of LAN for CS symptom control in NET patients are consistent regardless of baseline characteristics. Clinical trial information: NCT00774930

*LS mean, from subgroup ANCOVAs containing treatment, stratification factor(s) and baseline parameters (octreotide, diarrhea and flushing events), intent-to-treat population.